Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Alkermes plc

Rank #224DeclineWatchlistCompare with other stocks

ALKS · Nasdaq · Healthcare

Alkermes plc (ALKS) — Rank #224 by gross profitability (GP/assets 0.29) · ROE 13.4% · Piotroski F-Score N/A.

As-of 2026-10-30 · CIK 0001520262 · all metrics point-in-time as of the filing date.

About

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Show more

The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.

Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/E, P/B, and dividend yield matter most — book value provides a floor.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

2,050

Industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

9/11

Flags passed

ALKS fails 2 critical flags

Passes 9 of 11 quality flags

  • FAIL
    Revenue declining YoY

    Revenue contracted year over year

  • FAIL
    Operating margin declining

    Operating margin lower than prior year

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Revenue growth accelerating

No data Balance sheet — not counted as a pass.

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.29
Return on equity
13.4%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
1.43
Current ratio
2.30×
Net cash
-$811.48M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
6.7%

Growth

1/2 pass
Revenue growth
-5.2%
Piotroski F-Score
N/A
Share dilution
-0.3%

Asset value and restructuring potential (balance-sheet strength) are the primary reads at this stage.

Profitability

Does it make money well?

Warning: Operating margin declining, Revenue declining YoY · GP/assets 0.29

Gross profitability (GP / assets)

0.29

Primary signal (Novy-Marx).

8th of 12 SIC 2834 peers

Return on equity

13.4%

Gross margin

86.7%

5th of 12 SIC 2834 peers

Revenue growth (YoY)

-5.2%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

9.9%

Revenue CAGR (5Y)

7.3%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 99% above net income

Free cash flow

$480.33M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

98.8%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

6.7%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net debt $811.48M

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.43

12th of 12 SIC 2834 peers (best = lowest)

Current ratio

2.30×

8th of 12 SIC 2834 peers

Quick ratio

1.68×

Net cash

-$811.48M

Cash & equivalents minus total debt.

Piotroski F-Score

N/A

Only 8/9 components determinable.

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

2.3 / 5

Fair
Share count trend(net buybacks)
-0.3%3/5 Good
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory
-9.5%1/5 Weak

Lifecycle Phase History

20202025
Decline
Startup
Hypergrowth
Value

Price History

ALKS+40.5% · +7.0% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports